Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Microbes that reside peaceably in the nasal passageways and on the skin can be harnessed for taking drugs to target cells.

The platform leverages the nasal cavity's rich vascularization for both local and systemic drug delivery, which could be beneficial for treating respiratory conditions, central nervous system ...

The filing represents Polyrizon's ongoing efforts to protect its intellectual property and strengthens the company's position in the field of advanced nasal drug delivery. The T&T platform boasts ...

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Biopharmaceutical Drug Delivery Technologies Market The global biopharmaceutical drug delivery technologies <a target=_blank href=https: ...

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

MDR Certification Strengthens Resyca's Leadership in Soft Mist Drug-Device Combination Products ENSCHEDE, NL / ACCESS Newswire / January 28, 2025 / Resyca BV, a pioneering leader in the development an ...

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...